Real-world Management of Oral Factor Xa inhibitor-related Bleeds With Reversal Or Replacement Agents Including Andexanet Alfa and four-factor Prothrombin Complex Concentrate: A Multicenter Study

References

• Ziakas PD , KourbetiIS, PoulouLS, VlachogeorgosGS, MylonakisE. Medicare part D prescribing for direct oral anticoagulants in the United States: cost, use and the “rubber effect”. PLoS One, 13(6), e0198674 (2018).
   PubMed Web of Science ®Google Scholar
• Barnes GD , LucasE, AlexanderGC, GoldbergerZD. National trends in ambulatory oral anticoagulant use. Am. J. Med., 128(12), 1300-5.e2 (2015).
   PubMed Web of Science ®Google Scholar
• Lutsey PL , WalkerRF, MacLehoseRF, AlonsoA, AdamTJ, ZakaiNA. Direct oral anticoagulants and warfarin for venous thromboembolism treatment: trends from 2012 to 2017. Res. Pract. Thromb. Haemost., 3, 668–673 (2019).
   PubMed Web of Science ®Google Scholar
• January CT , WannLS, CalkinsHet al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm, 16(8), e66–e93 (2019).
   PubMed Web of Science ®Google Scholar
• Kearon C , AklEA, OrnelasJet al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest, 149(2), 315–352 (2016).
   PubMed Web of Science ®Google Scholar
• Konstantinides SV , MeyerG, BecattiniCet al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur. Heart J., 41(4), 543–603 (2020).
   PubMed Web of Science ®Google Scholar
• López-López JA , SterneJAC, ThomHHZet al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost effectiveness analysis. BMJ, 359 (2017).
   Google Scholar
• Ruff CT , GiuglianoRP, BraunwaldEet al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet, 383(9921), 955–962 (2014).
   PubMed Web of Science ®Google Scholar
• Dinkelaar J , PatiwaelS, HarenbergJ, LeyteA, BrinkmanHJ. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate. Clin. Chem. Lab. Med., 52(11), 1615–1623 (2014).
   PubMed Web of Science ®Google Scholar
• Solbeck S , MeyerMA, JohanssonPIet al. Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography. Int. J. Cardiol., 176(3), 794–799 (2014).
   PubMed Web of Science ®Google Scholar
• Majeed A , ÅgrenA, HolmströmMet al. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood, 130(15), 1706–1712 (2017).
   PubMed Web of Science ®Google Scholar
• Schulman S , GrossPL, RitchieBet al. Prothrombin complex concentrate for major bleeding on factor Xa inhibitors: a prospective cohort study. Thromb. Haemost., 118(5), 842–851 (2018).
   PubMed Web of Science ®Google Scholar
• Lu G , LinJP, BuiK, CurnutteJT, ConleyPB. Prothrombin complex concentrates (PCCs) have limited effect on TF-initiated thrombin generation in FXa inhibitor-anticoagulated plasma: in vitro comparison between direct reversal by andexanet alfa and “work around” by PCCs. Blood, 134(Suppl. 1), 713 (2019).
   PubMedGoogle Scholar
• Connolly SJ , CrowtherM, EikelboomJWet al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N. Engl. J. Med., 380(14), 1326–1335 (2019).
   PubMed Web of Science ®Google Scholar
• Tomaselli GF , MahaffeyKW, CukerAet al. 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on expert consensus decision pathways. J. Am. Coll. Cardiol., 70(24), 3042–3067 (2017).
   PubMed Web of Science ®Google Scholar
• Baugh CW , LevineM, CornuttDet al. Anticoagulant reversal strategies in the emergency department setting: recommendations of a Multidisciplinary Expert Panel. Ann. Emerg. Med., S0196-0644(19), 31181–31183 (2019).
   Google Scholar
• Gibler WB , RacadioJM, HirschAL, RoatTW. Management of Severe Bleeding in Patients Treated With Oral Anticoagulants: Proceedings Monograph From the Emergency Medicine Cardiac Research and Education Group-International Multidisciplinary Severe Bleeding Consensus Panel October 20, 2018. Crit Pathw Cardiol., 18(3), 143–166 (2019).
   PubMedGoogle Scholar
• Gerner ST , KuramatsuJB, SembillJAet al. Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage. Ann. Neurol., 83(1), 186–196 (2018).
   PubMed Web of Science ®Google Scholar
• Panos NG , CookAM, JohnS, JonesGM. Neurocritical Care Society (NCS) Pharmacy Study Group. Factor Xa inhibitor-related intracranial hemorrhage: results from a multicenter, observational cohort receiving prothrombin complex concentrates. Circulation., 141(21), 1681–1689 (2020).
   PubMed Web of Science ®Google Scholar
• Deitelzweig S , NeumanWR, Lingohr-SmithM, MengesB, LinJ. Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors. J. Med. Econ., 20(12), 1217–1223 (2017).
   PubMed Web of Science ®Google Scholar
• Happe LE , RaoSV, HorblyukR, FranklinM, LunacsekOE, MendittoL. Consequences of major bleeding in hospitalized patients with non-ST segment elevation acute coronary syndromes receiving injectable anticoagulants. Curr. Med. Res. Opin., 25(2), 413–420 (2009).
   PubMed Web of Science ®Google Scholar
• Ostermann H , HaertelS, KnaubS, KalinaU, JungK, PabingerI. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. Thromb. Haemost., 98(4), 790–797 (2007).
   PubMed Web of Science ®Google Scholar
• Siegal DM , CurnetteJT, ConnollySJet al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N. Engl. J. Med., 373(25), 2413–2424 (2015).
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration . Science and research special topics: real-world evidence (2020). www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence
   Google Scholar
• Fralick M , KesselheimAS, AvornJ, SchneeweissS. Use of health care databases to support supplemental indications of approved medications. JAMA Intern. Med., 178(1), 55–63 (2018).
   PubMed Web of Science ®Google Scholar